Jyoti Srivastava, PhD, discusses a study investigating methods to boost inhibitor function in advanced melanoma.
Videos
Panelists discuss how frequent phlebotomy requirements—typically more than 4 to 6 times per year—serve as a marker of inadequate disease control in polycythemia vera (PV), prompting consideration of cytoreductive therapy to improve hematologic stability, alleviate symptoms, and reduce thrombotic risk.
Panelists discuss how difficult-to-diagnose cases of chronic graft-vs-host disease (cGVHD) often include pulmonary involvement, gynecological manifestations, and neurological symptoms.
Panelists discuss how the decision to initiate cytoreductive therapy in polycythemia vera (PV) is driven by high-risk features such as age over 60 and thrombotic history, as well as factors like inadequate hematocrit control, symptom burden, and intolerance to phlebotomy, with therapy tailored to individual patient needs and goals.
A panelist discusses how successful management of chronic graft-vs-host disease (cGVHD) requires a multifaceted approach that combines prompt recognition, strategic intervention, and comprehensive supportive care to optimize both disease control and quality of life for transplant survivors.
Panelists discuss how clinicians typically diagnose chronic graft-vs-host disease (cGVHD) based on clinical features rather than biopsies, except in atypical or uncertain cases.
Ahmad Abuhelwa, MD, discusses the significance of a study exploring statin use in patients with chronic lymphocytic leukemia.
A transformative milestone in cancer care has arrived in Central New Jersey with the reopening of the John Theurer Cancer Center at 80 James Street in Edison.
Neal Shore, MD, FACS, discusses sasanlimab and its potential impact for community oncologists when treating patients with high-risk non–muscle invasive bladder cancer.
Jason M. Hafron, MD, discusses IsoPSA, a novel prostate-specific antigen assay for patients with a PSA > 4ng/ml who are facing a decision on prostate biopsy.
Ahmad Abuhelwa, MD, discusses an analysis exploring the connection between statins and better outcomes in patients with CLL and SLL.
Ahmad Abuhelwa, MD, discusses the mechanisms of statins and how they can play a surprisingly beneficial role in patients with chronic lymphocytic leukemia.
Ahmad Tarhini, MD, PhD, provides data into his research looking at inherited genetic variations and genetic ancestry in patients with high-risk melanoma.
Felix Guerrero-Ramos, MD, PhD, discusses the importance of the findings from the SunRISe-1 study of TAR-200 in bladder cancer from the 2025 AUA Annual Meeting.
In interviews with Targeted Oncology, Ronan J. Kelly, MD, MBA, and David Zhen, MD, discuss the CheckMate 649 trial of nivolumab plus ipilimumab and look back on last year's ODAC meeting on its use in PD-L1–negative gastrointestinal cancers.
An expert discusses how addressing unmet needs in early diagnosis, treatment options, and long-term management, alongside exploring targeted therapies, combination approaches, and advancements in stem cell transplantation, holds promise for more effective and less toxic treatments for blastic plasmacytoid dendritic cell neoplasm (BPDCN).
An expert discusses how structuring clear roles, fostering communication, and using technology in the shared-care model between academic and community centers, alongside monitoring blood glucose levels, kidney function, and comorbidities, ensures effective collaboration and safe use of tagraxofusp (TAG) therapy.
An expert discusses how effective use of tagraxofusp in blastic plasmacytoid dendritic cell neoplasm (BPDCN) requires proactive monitoring for capillary leak syndrome, liver toxicity, and myelosuppression, with structured protocols and multidisciplinary coordination—especially in community settings—to ensure early intervention and safe, successful treatment delivery.
An expert discusses how treatment selection in blastic plasmacytoid dendritic cell neoplasm (BPDCN) involves balancing disease-specific targeting and patient fitness, with tagraxofusp remaining the frontline standard due to its efficacy and favorable hematologic recovery, whereas venetoclax/azacitidine may be reserved for less fit patients or relapsed settings.
An expert discusses how effective blastic plasmacytoid dendritic cell neoplasm (BPDCN) management requires early central nervous system (CNS) evaluation and a multidisciplinary approach, with treatment decisions guided by disease burden, patient fitness, and CNS involvement—highlighting the need for systemic tagraxofusp combined with prompt intrathecal therapy to address high-risk features.
Ahmad Tarhini, MD, PhD, discusses inherited genetic variations and genetic ancestry, particularly for patients with high-risk melanoma.
Panelists discuss how Janus kinase (JAK) inhibitors like pacritinib offer crucial treatment options for myelofibrosis patients with severe thrombocytopenia (platelet counts <50,000 ), highlighting its advantages in providing significant spleen volume reduction (29% vs 3% in PERSIST-2 trial) while also offering unexpected anemia benefits possibly due to ACVR1 inhibition, with clinicians noting they set realistic expectations about platelet stabilization rather than improvement when counseling patients.
Panelists discuss how Janus kinase (JAK) inhibitor dosing strategies must be carefully tailored for anemic myelofibrosis patients, with clinical experience suggesting starting at lower doses (10 mg twice daily ) and gradually escalating based on the REALIZE trial approach, while balancing efficacy goals against cytopenia risks and monitoring unique toxicity profiles of different JAK inhibitors including Wernicke encephalopathy with fedratinib and gastrointestinal issues with pacritinib.
Julie Brahmer, MD, discusses the unique features of the phase 3 CheckMate 9LA trial in patients with metastatic non–small cell lung cancer.
Mark D. Tyson, MD, MPH, discusses cretostimogene and how it varies from other therapies for bladder cancer.
Mark Tyson, MD, MPH, discusses practice-changing data from the phase 3 BOND-003 study.
An expert discusses how the diagnosis and management of blastic plasmacytoid dendritic cell neoplasm (BPDCN) require careful recognition of characteristic dermatologic and hematologic features, with tagraxofusp as frontline therapy and vigilant monitoring for central nervous system (CNS) involvement and treatment-related toxicities to guide a multidisciplinary care approach.
A panelist discusses how the MARIPOSA, SKIPPirr, and COCOON studies highlight the significant overall survival benefit of the amivantamab and lazertinib combination in first-line treatment for EGFR-mutant non–small cell lung cancer (NSCLC), while also emphasizing the importance of proactive management of adverse events (AEs), which may shift the standard of care and improve patient tolerability and adherence.
Panelists discuss how managing asymptomatic splenomegaly in myelofibrosis requires a nuanced approach, balancing observation in low-risk patients with early intervention using Janus kinase (JAK) inhibitors in higher-risk cases, while emphasizing the importance of regular monitoring, patient preferences, and shared decision-making.